{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"200"}],"units":"Participants"}],"description":"A serious adverse event (SAE) is an AE that is life-threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. The percentage of participants that experience at least one SAE that was reported as at least possibly related to the study vaccine was summarized.","groups":[{"description":"Participants received a single 0.5-mL intramuscular injection of the 9vHPV vaccine at Day 1, Month 2, and Month 6","id":"OG000","title":"9vHPV Vaccine"}],"paramType":"NUMBER","populationDescription":"All participants that received at least 1 vaccination with 9vHPV vaccine and provided safety data at any time during the study.","reportingStatus":"POSTED","timeFrame":"Up to 4 weeks postdose 3 (Month 7)","title":"Percentage of Participants With a Vaccine-related Serious Adverse Event","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}